Call for colleagues to take part in COVID-19 study
Published: 10 December 2021
COVID-19 DeplOyed VaccinE Cohort Study (DOVE) will study effectiveness of vaccines against variants
If you have received a primary course of vaccine and a booster dose, we invite you to take part in the COVID-19 DeplOyed VaccinE Cohort Study (DOVE). This is an observational cohort study run by NHS Greater Glasgow and Clyde and Glasgow University to determine the immunogenicity of deployed COVID-19 vaccines against evolving SARS-CoV-2 variants.
We are currently looking for volunteers for the study who have had at least 3 doses of vaccine more than 14 days ago to allow us to test responses against the omicron variant.
The aim of this research is to look at immune response levels (protection against infection) in people who have had at least one dose of any licenced COVID-19 vaccination against different variants of the virus that causes COVID-19 and other related viruses.
We are currently interested in
Individuals that have received three doses of vaccine more than 14 days ago.
What does it involve?
Attend the Clinical Trials Facility at the QEUH hospital, sign a consent form and agree to the collection of a blood sample (approximately 30mls).
Am I eligible to participate?
If you have received three doses of deployed vaccine (the last of which more than 14 days ago) and have never had a positive PCR or positive antibody test and are not on any immunosuppressant medication, you may be eligible. We are looking for people who have not previously had COVID-19.
If you would like to receive further information or take part in the study please email COVID Research CovidResearch@ggc.scot.nhs.uk and use the headline of this article in the email subject line.
To ensure the appropriate information is sent please advise if you have received one or two vaccine doses, which vaccine you have had and your date(s) of vaccination.
Thanks in advance to anyone who might be interested
Professor Emma Thomson PhD FRCP
MRC - University of Glasgow Centre for Virus Research
First published: 10 December 2021